OriGene Technologies, Inc.
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

Product datasheet for TL320729V

WNK1 Human shRNA Lentiviral Particle (Locus ID 65125)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	WNK1 Human shRNA Lentiviral Particle (Locus ID 65125)
Locus ID:	65125
Synonyms:	HSAN2; HSN2; KDP; p65; PPP1R167; PRKWNK1; PSK
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	WNK1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
RefSeq:	BC021121, NM_001184985, NM_014823, NM_018979, NM_213655, NM_213655.3, NM_213655.4, NM_018979.1, NM_018979.2, NM_018979.3, NM_014823.2, NM_001184985.1, BC130467, BC013629, BC035146, BC044600, BC071959, BC094862, BC130469, BC141881, BC172444, BM716053, NM_014823.3, NM_018979.4
UniProt ID:	Q9H4A3
Summary:	This gene encodes a member of the WNK subfamily of serine/threonine protein kinases. The encoded protein may be a key regulator of blood pressure by controlling the transport of sodium and chloride ions. Mutations in this gene have been associated with pseudohypoaldosteronism type II and hereditary sensory neuropathy type II. Alternatively spliced transcript variants encoding different isoforms have been described but the full-length nature of all of them has yet to be determined.[provided by RefSeq, May 2010]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.

View online »

Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).